The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
CME Symposium at the AACR Annual Meeting 2023
In order to attend this CME symposium, you MUST be registered for the AACR Annual Meeting 2023.
Date/Time:
Sunday, April 16th, 2023
Registration and Dinner | 6:30 – 7:00 pm ET
CME Symposium | 7:00 – 8:30 pm ET
Location:
Rosen Centre Hotel
Grand Ballroom A
9840 International Drive
Orlando, FL 32819
Program Overview:
Recent clinical trial results with PARP inhibitors have demonstrated improvement in radiological progression-free survival and other parameters potentially offering new combination treatments when available. Synergistic combinations of PARP inhibitors and androgen receptor targeted therapy may become the new treatment paradigm for metastatic castration-resistant prostate cancer. Breakthroughs in genetic testing have led to the development of novel therapies that target the PARP pathway of DNA repair. Healthcare providers need to be current on the latest clinical trial data and clinical applications of emerging PARP inhibitor/androgen receptor combination therapies to inform clinical decision making. Please join our expert faculty as they discuss these research advances and place them within a practical and contemporary clinical context for developing and maintaining updated care pathways for persons suffering from advanced prostate cancer.
Agenda
I. Scientific Update: Mechanism of Action and Clinical Rationale for PARP-Inhibitors and PARP-Inhibitor/Androgen Receptor Combinations & Ongoing Research Studies
II. Clinical Trial Data and Clinical Applications for New and Emerging Therapies Including PARP-Inhibitors Combined with Androgen Receptor Targeted Therapies
III. Practical Strategies to Update Treatment Plans to Consider the Potential Role of PARP- Inhibitor Combinations to Improve Outcomes in Patients with mCRPC
Educational Objectives:
1. Review the science, mechanism of action and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen receptor combinations to treat patients with mCRPC
2. Analyze current clinical trial data and clinical applications for new and emerging therapies, including PARP-inhibitors combined with androgen receptor targeted therapies
3. Review the evolving paradigm of potential treatment strategies and patient adherence factors for PARP inhibitor combinations to improve outcomes in patients with mCRPC
Faculty:
Alan Tan, MD (Course Chair)
Director of GU Medical Oncology
Assistant Professor, Department of Internal Medicine
Division of Hematology, Oncology and Cell Therapy
RUSH Medical College
Chicago, Illinois
Alan H. Bryce, MD
Chair, Division of Hematology and Medical Oncology
Mayo Clinic Arizona
Phoenix, Arizona
Maha Hussain, MD
Genevieve Teuton Professor of Medicine
Division of Hematology-Oncology, Department of Medicine
Northwestern University Feinberg School of Medicine
Deputy Director, GU Oncology Program
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois
Accreditation Statement:
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
AcademicCME designates this live material for a maximum of 1.50 AMA PRA Category 1 CreditsTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs:
For all CE inquiries or special needs, please contact [email protected] or 610-687-3300.
Financial Support
This symposium is supported by an independent educational grant from Pfizer Inc.
In order to attend this CME symposium, you MUST be registered for the AACR Annual Meeting 2023.
This symposium is sponsored by AcademicCME and supported by a grant from Pfizer Inc. This is not an official program of the American Association for Cancer Research Annual Meeting.
